Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) is now available.
Jiangsu Hengrui Pharmaceuticals has scheduled a board meeting for April 22, 2026, to review and approve the quarterly results for the three months ended March 31, 2026, and to authorize their publication. The announcement signals the upcoming disclosure of the company’s latest financial and operational performance, which will be closely watched by investors and other stakeholders for indications of business momentum and strategic progress.
The notice also reconfirms the current composition of the board of directors, including its executive, non-executive and independent non-executive members. This underlines continuity in the company’s governance framework ahead of the results release, offering stakeholders visibility on the leadership responsible for overseeing financial reporting and corporate decision-making.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$92.00 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a China-based pharmaceutical company listed in Hong Kong, focusing on the research, development and commercialization of innovative drugs and related therapies. The group operates through multiple subsidiaries and is overseen by a board comprising executive, non-executive and independent non-executive directors, reflecting a standard listed-company governance structure.
Average Trading Volume: 3,255,136
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$434.9B
For a thorough assessment of 1276 stock, go to TipRanks’ Stock Analysis page.